SC3613

SC3613 (also known as IN-207387) is an orally active, mutant-selective heterobifunctional degrader targeting the epidermal growth factor receptor (EGFR). Developed by Dong-A ST and HK inno.N, it is designed to selectively bind an allosteric pocket of mutant EGFR while sparing the wild-type receptor, thereby minimizing off-target toxicities such as cutaneous adverse effects. SC3613 induces ubiquitin-proteasome-mediated degradation of EGFR variants harboring activating and resistance mutations, including L858R, T790M, and C797S. In preclinical models of EGFR TKI-resistant non-small cell lung cancer (NSCLC), the compound has demonstrated potent anti-tumor activity, including durable complete tumor regressions, and a superior safety profile compared to third-generation TKIs like osimertinib.